Skip to main content
Top
Published in: Journal of Cancer Survivorship 2/2015

01-06-2015

An algorithm to identify the development of lymphedema after breast cancer treatment

Authors: Tina W. F. Yen, Purushuttom W. Laud, Rodney A. Sparapani, Jianing Li, Ann B. Nattinger

Published in: Journal of Cancer Survivorship | Issue 2/2015

Login to get access

Abstract

Purpose

Large, population-based studies are needed to better understand lymphedema, a major source of morbidity among breast cancer survivors. One challenge is identifying lymphedema in a consistent fashion. We sought to develop and validate an algorithm using Medicare claims to identify lymphedema after breast cancer surgery.

Methods

From a population-based cohort of 2,597 elderly (65+) women who underwent incident breast cancer surgery in 2003 and completed annual telephone surveys through 2008, two algorithms were developed using Medicare claims from half of the cohort and validated in the remaining half. A lymphedema-positive case was defined by patient report.

Results

A simple two ICD-9 code algorithm had 69 % sensitivity, 96 % specificity, positive predictive value >75 % if prevalence of lymphedema is >16 %, negative predictive value >90 %, and area under receiver operating characteristic curve (AUC) of 0.82 (95 % CI 0.80–0.85). A more sophisticated, multi-step algorithm utilizing diagnostic and treatment codes, logistic regression methods, and a reclassification step performed similarly to the two-code algorithm.

Conclusions

Given the similar performance of the two validated algorithms, the ease of implementing the simple algorithm and the fact that the simple algorithm does not include treatment codes, we recommend that this two-code algorithm be validated in and applied to other population-based breast cancer cohorts.

Implications for Cancer Survivors

This validated lymphedema algorithm will facilitate the conduct of large, population-based studies in key areas (incidence rates, risk factors, prevention measures, treatment, and cost/economic analyses) that are critical to advancing our understanding and management of this challenging and debilitating chronic disease.
Literature
1.
go back to reference Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc. 1986;81:461–70.CrossRef Efron B. How biased is the apparent error rate of a prediction rule? J Am Stat Assoc. 1986;81:461–70.CrossRef
2.
go back to reference Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 Suppl):IV-43-8.PubMed Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 Suppl):IV-43-8.PubMed
3.
go back to reference McClish DK, Penberthy L, Whittemore M, Newschaffer C, Woolard D, Desch CE, et al. Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. Am J Epidemiol. 1997;145:227–33.CrossRefPubMed McClish DK, Penberthy L, Whittemore M, Newschaffer C, Woolard D, Desch CE, et al. Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. Am J Epidemiol. 1997;145:227–33.CrossRefPubMed
6.
go back to reference Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39:1733–49.PubMedCentralCrossRefPubMed Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39:1733–49.PubMedCentralCrossRefPubMed
7.
go back to reference Freeman JL, Zhang D, Freeman DH, Goodwin JS. An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol. 2000;53:605–14.CrossRefPubMed Freeman JL, Zhang D, Freeman DH, Goodwin JS. An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol. 2000;53:605–14.CrossRefPubMed
8.
go back to reference Warren JL, Feuer E, Potosky AL, Riley GF, Lynch CF. Use of Medicare hospital and physician data to assess breast cancer incidence. Med Care. 1999;37:445–56.CrossRefPubMed Warren JL, Feuer E, Potosky AL, Riley GF, Lynch CF. Use of Medicare hospital and physician data to assess breast cancer incidence. Med Care. 1999;37:445–56.CrossRefPubMed
9.
go back to reference Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009;15:659–68.PubMed Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009;15:659–68.PubMed
10.
11.
go back to reference Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.1097/MLR.0b013e318277eb6f. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi:10.​1097/​MLR.​0b013e318277eb6f​.
13.
go back to reference Lamont EB, Herndon 2nd JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98:1335–8. doi:10.1093/jnci/djj363.PubMedCentralCrossRefPubMed Lamont EB, Herndon 2nd JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, et al. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98:1335–8. doi:10.​1093/​jnci/​djj363.PubMedCentralCrossRefPubMed
14.
go back to reference McClish D, Penberthy L, Pugh A. Using Medicare claims to identify second primary cancers and recurrences in order to supplement a cancer registry. J Clin Epidemiol. 2003;56:760–7.CrossRefPubMed McClish D, Penberthy L, Pugh A. Using Medicare claims to identify second primary cancers and recurrences in order to supplement a cancer registry. J Clin Epidemiol. 2003;56:760–7.CrossRefPubMed
15.
go back to reference Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75-81.PubMed Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75-81.PubMed
18.
go back to reference Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. CA Cancer J Clin. 2000;50:292–307. quiz 8–11.CrossRefPubMed Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. CA Cancer J Clin. 2000;50:292–307. quiz 8–11.CrossRefPubMed
19.
go back to reference Sparaco A, Fentiman IS. 9. Arm lymphoedema following breast cancer treatment. Int J Clin Pract. 2002;56:107–10.PubMed Sparaco A, Fentiman IS. 9. Arm lymphoedema following breast cancer treatment. Int J Clin Pract. 2002;56:107–10.PubMed
20.
go back to reference Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49. doi:10.1002/cncr.27467.CrossRefPubMed Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, et al. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49. doi:10.​1002/​cncr.​27467.CrossRefPubMed
21.
go back to reference Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg. 1993;36:315–20.PubMed Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg. 1993;36:315–20.PubMed
23.
go back to reference Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14. doi:10.1200/JCO.2008.18.3517.CrossRefPubMed Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14. doi:10.​1200/​JCO.​2008.​18.​3517.CrossRefPubMed
25.
go back to reference Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93:96–111.CrossRefPubMed Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001;93:96–111.CrossRefPubMed
26.
go back to reference Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998;83(12 Suppl American):2776–81.CrossRefPubMed Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer. 1998;83(12 Suppl American):2776–81.CrossRefPubMed
27.
go back to reference Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.PubMedCentralPubMed Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. Lymphology. 2010;43:118–27.PubMedCentralPubMed
28.
go back to reference McLaughlin SA. Lymphedema: separating fact from fiction. Oncology. 2012;26:242–9.PubMed McLaughlin SA. Lymphedema: separating fact from fiction. Oncology. 2012;26:242–9.PubMed
29.
31.
go back to reference From cancer patient to cancer survivor: lost in translation. 1 ed. Washington, D.C.: National Academies Press; 2005. From cancer patient to cancer survivor: lost in translation. 1 ed. Washington, D.C.: National Academies Press; 2005.
35.
go back to reference ICD-9 CM International classification of diseases, 9th revision. Millenium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007. ICD-9 CM International classification of diseases, 9th revision. Millenium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007.
36.
go back to reference Current Procedural Terminology: CPT 2004. Chicago: American Medical Association; 2003. Current Procedural Terminology: CPT 2004. Chicago: American Medical Association; 2003.
37.
go back to reference HCPCS Health Care Financing Administration Common Procedure Coding System. National Level II Medicare Codes. Millennium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007. HCPCS Health Care Financing Administration Common Procedure Coding System. National Level II Medicare Codes. Millennium edition. 2008. Los Angeles: Practice Management Information Corporation; 2007.
38.
go back to reference Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002;20:4242–8.CrossRefPubMed Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol. 2002;20:4242–8.CrossRefPubMed
42.
go back to reference International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus Document of the International Society of Lymphology. Lymphology. 2009;42:51–60. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus Document of the International Society of Lymphology. Lymphology. 2009;42:51–60.
43.
Metadata
Title
An algorithm to identify the development of lymphedema after breast cancer treatment
Authors
Tina W. F. Yen
Purushuttom W. Laud
Rodney A. Sparapani
Jianing Li
Ann B. Nattinger
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 2/2015
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0393-z

Other articles of this Issue 2/2015

Journal of Cancer Survivorship 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine